Progression patterns after EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated (EGFR-mut+) non small cell lung cancers (NSCLCs): Correlations with clinical oucomes.

e20600Background: EGFR-mut+ NSCLCs represent a distinct molecular subtype with improved outcome when treated with EGFR TKIs. However, virtually all EGFR-mut+ pts ultimately progress. We sought to a...